Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | GEN-009 |
Trade Name | |
Synonyms | GEN009|GEN 009 |
Drug Descriptions |
GEN-009 is a personalized cancer vaccine developed from identified neoantigens in solid tumors in the form of synthetic long peptides (SLPs) (Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019) 2611-2611). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C162874 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
GEN-009 | GEN-009 | 0 | 1 |
GEN-009 + Nivolumab | GEN-009 Nivolumab | 0 | 1 |
GEN-009 + unspecified PD-1 antibody | GEN-009 unspecified PD-1 antibody | 0 | 0 |